Abstract | OBJECTIVE: METHODS: RESULTS: CONCLUSION: RA may potentiate the risk of cutaneous malignancy and therefore dermatologic screening in this population should be considered. The use of immunomodulatory therapy in RA, psoriasis, and PsA may further increase the risk of cutaneous malignancy and therefore dermatologic screening examinations are warranted in these groups. More careful recording of skin cancer development during clinical trials and cohort studies is necessary to further delineate the risks of immunomodulatory therapy.
|
Authors | Michael S Krathen, Alice B Gottlieb, Philip J Mease |
Journal | The Journal of rheumatology
(J Rheumatol)
Vol. 37
Issue 11
Pg. 2205-15
(Nov 2010)
ISSN: 0315-162X [Print] Canada |
PMID | 20810498
(Publication Type: Journal Article, Review)
|
Chemical References |
|
Topics |
- Arthritis, Psoriatic
(therapy)
- Arthritis, Rheumatoid
(therapy)
- Humans
- Immunologic Factors
(adverse effects)
- Immunosuppression Therapy
(adverse effects)
- Psoriasis
(therapy)
- Skin Neoplasms
(etiology)
|